

Leishmaniasis

UGANDA

2014
*Published in July 2016
Updated in September 2016*

Country General Information (WHO, 2013)

Total population:	36,573,387	Age group <15/>14 years, %:	48% / 52%
Gender (% F/M):	49.9% / 50.1%	Life expectancy at birth in years (F/M):	61 / 57
GDP (PPP int \$)	1370	Number of 3rd sub-national administrative level divisions, name:	146, County
Income status:	Low		


Epidemiology

	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Non endemic	Non endemic	Non endemic
Number of new cases (incidence):	131	N/A	N/A	N/A
Number of relapse cases:	4	N/A	N/A	N/A
Total number of cases:	135	N/A	N/A	N/A
Imported cases (n, %):	103 76%	No data	N/A	N/A
Gender distribution (% F):	24%	N/A	N/A	N/A
Age group distribution (% <5/5-14/>14):	(15/50/38)	N/A	N/A	N/A
Incidence rate (cases/10 000 population in endemic areas):	No data	N/A	N/A	N/A
Endemic 3rd sub-national administrative level divisions for VL or CL (n):	No data	N/A	N/A	N/A
Population at risk ¹ (% n/total):	No data	N/A	N/A	N/A
Was there any outbreak?	Unknown	Not available	N/A	N/A
Number of new ² foci:	0	Not available	N/A	N/A

N/A = not applicable VL = visceral leishmaniasis CL = cutaneous leishmaniasis PKDL = post-kala-azar dermal leishmaniasis MCL = mucocutaneous leishmaniasis


Monthly distribution of new cases January-December

2014	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	12	5	19	13	9	11	18	11	6	20	0	11
CL	0	0	0	0	0	0	0	0	0	0	0	0



Incidence rate/10 000 population and number of new CL (left) and new (primary) VL (right) cases from 1998 to 2014

Not endemic for CL



¹ Defined as "Number of people living in 3rd sub-national administrative level endemic areas"

* No data available

² For this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever

³ Incidence rate at the national level

Distribution of new CL (left) and new (primary) VL (right) cases

Not endemic for CL

No data reported on the provenance of the VL cases,
but all the cases were reported from one health facility in Amudat district (Northern region).

Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established:	Not available	Year latest national guidelines were published:	Not available
Type of surveillance:	Not available	Is leishmaniasis a notifiable disease (mandatory reporting)?	Not available
Is there a vector control programme?	Not available	Is there a reservoir host control programme?	Not available
Type of insecticide used for IRS:	Not available	Number of leishmaniasis health facilities:	Not available

Diagnosis

	VL	CL	PKDL	MCL
Number of people screened actively for:	109	N/A	N/A	N/A
Number of people screened passively for:	297	N/A	N/A	N/A
VL cases diagnosed by RDT* (%, RDT+/total VL cases):	0% (0/131)	N/A	N/A	N/A
Proportion of positive RDT* (%, RDT+/total RDT):	26% (107/406)	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% slides +/total cases):	100% (135/135)	N/A	N/A	N/A
Proportion of positive slides (%, slides +/total slides):	No data	N/A	N/A	N/A
Cases diagnosed clinically (%, nb clinical cases/total cases):	0% (0/135)	N/A	N/A	N/A
Percentage of cases with HIV-VL coinfection:	0% (0/135)	N/A	N/A	N/A

* These indicators apply only for new (primary) VL cases
 VL = visceral leishmani
 CL = cutaneous leishmaniasis
 PKDL = post-kala-azar dermal leishmaniasis
 N/A = not applicable
 RDT: rapid diagnostic test
 HIV: human Immunodeficiency virus
 MCL = mucocutaneous leishmaniasis

Treatment and medicines

Is treatment provided free of charge in the public sector?	Not available
Antileishmanial medicines included in the national List of Essential Medicines:	Not available

TREATMENT OUTCOME

	VL
Proportion of relapse cases: ³	3% (4/135)
Initial cure rate:	100% (131/131)
Failure ⁴ rate:	0% (0/131)
Case-fatality rate:	0% (0/131)

³ A relapse case in this country is defined as:

No definition available

⁴ A failure case in this country is defined as:

No definition available

Data source: Ministry of Health, Kenya and Drugs for Neglected Diseases initiative (DNDI)
 © WHO 2014. All rights reserved.